Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?

144Citations
Citations of this article
126Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

HPV-driven oropharyngeal cancers have significantly better survival rates than tobacco and alcohol induced head and neck cancers. As HPV-positive patients are younger, healthier and far more likely to survive their disease, long-term treatment side effects are becoming a major issue. This has led the scientific and medical community to reassess the current treatment protocols in order to develop less toxic strategies while maintaining good oncological outcomes. In this article, we discuss the ongoing treatment de-escalation trials and highlight the issues raised by these studies.

Cite

CITATION STYLE

APA

Mirghani, H., & Blanchard, P. (2018, January 1). Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand? Clinical and Translational Radiation Oncology. Elsevier Ireland Ltd. https://doi.org/10.1016/j.ctro.2017.10.005

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free